Neil Harris Cohen net worth and biography

Neil Cohen Biography and Net Worth

Director of Chemomab Therapeutics

Neil Cohen served as interim CEO of Anchiano Therapeutics (NASDAQ: ANCN) from October 2020 until its merger with Chemomab in March 2021. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings. He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A., with first class honors, from Oxford University.

What is Neil Harris Cohen's net worth?: The estimated net worth of Neil Harris Cohen is at least $13,800.00 as of November 16th, 2022. Cohen owns 10,000 shares of Chemomab Therapeutics stock worth more than $13,800 as of November 2nd. This net worth estimate does not reflect any other investments that Cohen may own. Learn More about Neil Harris Cohen's net worth.
How do I contact Neil Harris Cohen?: The corporate mailing address for Cohen and other Chemomab Therapeutics executives is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. Chemomab Therapeutics can also be reached via phone at 972-77-331-0156 and via email at [email protected]. Learn More on Neil Harris Cohen's contact information.
Has Neil Harris Cohen been buying or selling shares of Chemomab Therapeutics?: Neil Harris Cohen has not been actively trading shares of Chemomab Therapeutics within the last three months. Most recently, Neil Harris Cohen sold 2,409 shares of the business's stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $2.00, for a transaction totalling $4,818.00. Following the completion of the sale, the director now directly owns 10,000 shares of the company's stock, valued at $20,000. Learn More on Neil Harris Cohen's trading history.

Neil Harris Cohen Insider Trading History at Chemomab Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2022	Sell	2,409	$2.00	$4,818.00	10,000
3/14/2022	Buy	6,000	$4.35	$26,100.00
12/6/2021	Buy	2,000	$7.43	$14,860.00

Neil Harris Cohen Buying and Selling Activity at Chemomab Therapeutics

Chemomab Therapeutics Company Overview

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Today's Range

Now: $1.38

$1.36

$1.46

50 Day Range

MA: $1.64

$1.13

$2.46

2 Week Range

Now: $1.38

$0.42

$2.55

Volume

36,597 shs

Average Volume

189,181 shs

Market Capitalization

$19.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.